Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients

doi:10.3748/wjg.v25.i11.1398

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7854)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

460

WORD

164

HTML

4115

Figures (1-4)

323

Tables (1-2)

229

Sum=5291

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

970

Download

1593

Sum=2563

Mar 21, 2019 (publication date) through Nov 14, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Mar 21, 2019; 25(11): 1398-1408
Published online Mar 21, 2019. doi: 10.3748/wjg.v25.i11.1398

Full Size Figure Download Figure

Figure 4 Cumulative incidence of hepatocellular carcinoma according to baseline serum Mac-2 binding protein glycosylation isomer level. COI: Cut-off index; HCC: Hepatocellular carcinoma; M2BPGi: Mac-2 binding protein glycosylation isomer.

Citation: Mak LY, To WP, Wong DKH, Fung J, Liu F, Seto WK, Lai CL, Yuen MF. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. World J Gastroenterol 2019; 25(11): 1398-1408
URL: https://www.wjgnet.com/1007-9327/full/v25/i11/1398.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i11.1398